The release of the substrate for xanthine oxidase in hypertensive patients was suppressed by angiotensin converting enzyme inhibitors and α1-blockers

被引:21
作者
Ohtahara, A
Hisatome, I
Yamamoto, Y
Furuse, M
Sonoyama, K
Furuse, Y
Hamada, T
Katoh, M
Watanabe, M
Kinugawa, T
Ogino, K
Igawa, O
Shimomura, T
Murakami, F
Yamamoto, T
Shigemasa, C
机构
[1] Tottori Univ, Fac Med, Dept Med 1, Yonago, Tottori 683, Japan
[2] Tottori Univ, Fac Med, Dept Clin Lab Med, Yonago, Tottori 683, Japan
[3] Hyogo Coll Med, Dept Med 3, Nishinomiya, Hyogo, Japan
关键词
hypertension; skeletal muscle; hypoxia; alpha(1)-blocker; ACE inhibitor; hypoxanthine; uric acid;
D O I
10.1097/00004872-200103001-00009
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Objective Hyperuricemia is associated with the vascular injury of hypertension, and purine oxidation may play a pivotal role in this association, but the pathophysiology is not fully understood. We tested the hypothesis that in hypertensive patients, the excess amount of the purine metabolite, hypoxanthine, derived from skeletal muscles, would be oxidized by xanthine oxidase, leading to myogenic hyperuricemia as well as to impaired vascular resistance caused by oxygen radicals. Methods We investigated the production of hypoxanthione, the precursor of uric acid and substrate for xanthine oxidase, in hypertensive patients and found that skeletal muscles produced hypoxanthine in excess. We used the semi-ischemic forearm test to examine the release of hypoxanthine (Delta HX), ammonium (Delta Amm) and lactate (Delta LAC) from skeletal muscles in essential hypertensive patients before (UHT: n = 88) and after treatment with antihypertensive agents (THT: n = 37) in comparison to normotensive subjects (NT: n = 14), Results Delta HX, as well as Delta Amm and Delta LAC, were significantly higher in UHT and THT (P < 0.01) than in NT, This release of <Delta>HX from exercising skeletal muscles correlated significantly with the elevation of lactate in NT, UHT and THT (y = 0.209 + 0.031 x; R-2 = 0.222, n = 139: P < 0.01). Administration of doxazosin (n = 4), bevantolol (n = 5) and alacepll (n = 8) for 1 month significantly suppressed the ratio of percentage changes in <Delta>HX by -38.4 +/- 55.3%, -51.3 +/- 47.3% and -76.3 +/- 52.2%, respectively (P < 0.05) but losartan (n = 3), atenolol (n = 7) and manidipine (n = 10) did not reduce the ratio of changes; on the contrary, they increased it in <Delta>HX by + 188.2 +/- 331%, + 96.2 +/- 192.2% and + 42.8 +/- 137.3%, respectively. The elevation of Delta HX after exercise correlated significantly with the serum concentration of uric acid at rest in untreated hypertensive patients (y = 0.194 - 0,255x; R-2 = 0.185, n = 30: P < 0.05), The prevalence of reduction of both <Delta>HX and serum uric acid was significantly higher in the patients treated with alacepril, bevantolol and doxazosin (67%: P < 0.02) than in the patients treated with losartan, atenolol and manidipine (12%), Conclusions It is concluded that the skeletal muscles of hypertensive patients released <Delta>HX in excess by activation of muscle-type adenosine monophosphate (AMP) deaminase, depending on the degree of hypoxia, The modification of Delta HX by angiotensin-converting enzyme inhibitors and alpha (1)-blockers influenced the level of serum uric acid, suggesting that the skeletal muscles may be an important source of uric acid as well as of the substrate of xanthine oxidase in hypertension.
引用
收藏
页码:575 / 582
页数:8
相关论文
共 49 条
  • [1] BINDING OF HUMAN XANTHINE-OXIDASE TO SULFATED GLYCOSAMINOGLYCANS ON THE ENDOTHELIAL-CELL SURFACE
    ADACHI, T
    FUKUSHIMA, T
    USAMI, Y
    HIRANO, K
    [J]. BIOCHEMICAL JOURNAL, 1993, 289 : 523 - 527
  • [2] Alderman M.H., 1998, AM J HYPERTENS, V2, p16A
  • [3] Serum uric acid and cardiovascular events in successfully treated hypertensive patients
    Alderman, MH
    Cohen, H
    Madhavan, S
    Kivlighn, S
    [J]. HYPERTENSION, 1999, 34 (01) : 144 - 150
  • [4] Relation between serum uric acid and lower limb blood flow in patients with chronic heart failure
    Anker, SD
    Leyva, F
    PooleWilson, PA
    Kox, WJ
    Stevenson, JC
    Coats, AJS
    [J]. HEART, 1997, 78 (01) : 39 - 43
  • [5] BASSETT DR, 1994, MED SCI SPORT EXER, V26, P957
  • [6] TOWARDS THE PHYSIOLOGICAL-FUNCTION OF URIC-ACID
    BECKER, BF
    [J]. FREE RADICAL BIOLOGY AND MEDICINE, 1993, 14 (06) : 615 - 631
  • [7] OVERNIGHT URINARY URIC-ACID - CREATININE RATIO FOR DETECTION OF SLEEP HYPOXEMIA - VALIDATION-STUDY IN CHRONIC OBSTRUCTIVE PULMONARY-DISEASE AND OBSTRUCTIVE SLEEP-APNEA BEFORE AND AFTER TREATMENT WITH NASAL CONTINUOUS POSITIVE AIRWAY PRESSURE
    BRAGHIROLI, A
    SACCO, C
    ERBETTA, M
    RUGA, V
    DONNER, CF
    [J]. AMERICAN REVIEW OF RESPIRATORY DISEASE, 1993, 148 (01): : 173 - 178
  • [8] PROPRANOLOL ENHANCES ADENINE-NUCLEOTIDE DEGRADATION IN HUMAN-MUSCLE DURING EXERCISE
    BROBERG, S
    KATZ, A
    SAHLIN, K
    [J]. JOURNAL OF APPLIED PHYSIOLOGY, 1988, 65 (06) : 2478 - 2483
  • [9] Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients
    Cardillo, C
    Kilcoyne, CM
    Cannon, RO
    Quyyumi, AA
    Panza, JA
    [J]. HYPERTENSION, 1997, 30 (01) : 57 - 63
  • [10] Divergent effects of ACE-inhibition and calcium channel blockade on NO-activity in systemic and renal circulation in essential hypertension
    Dijkhorst-Oei, LT
    Beutler, JJ
    Stroes, ESG
    Koomans, HA
    Rabelink, TJ
    [J]. CARDIOVASCULAR RESEARCH, 1998, 40 (02) : 402 - 409